International Patent: APHERESIS-DERIVED MONONUCLEAR CELL PRODUCT THAT PRESERVES FUNCTIONAL BIOLOGICAL ACTIVITY OF PURIFIED SUBPOPULATIONS OF CELLS FOR CELL THERAPY WITH CONSISTENT, RELIABLE AND REPRODUCIBLE PROPERTIES

GENEVA, Nov. 6 -- ACHIEVE CLINICS, INC filed a patent application (US2026/026044) for “APHERESIS-DERIVED MONONUCLEAR CELL PRODUCT THAT PRESERVES FUNCTIONAL BIOLOGICAL ACTIVITY OF PURIFIED SUBPOPULATIONS OF CELLS FOR CELL THERAPY WITH CONSISTENT, RELIABLE AND REPRODUCIBLE PROPERTIES”. With publication no. WO/2026/231940, here are the other details related to the patent application:

Kind: Initial Publication with ISR [A1]

IPC: C12N 5/0786

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Disclaimer: Curated by HT Syndication....